MENU
APR 28, 2021 9:00 AM PDT

Combining protein proximity detection with chromogenic multiplex: Discovering the PD1/PDL1 interactions

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

DISCOVERY Proximity detection is a powerful technique for demonstrating the presence of 2 unique targets in direct proximity of each other in tissue sections. It allows visualization of interacting proteins in distance of 40 nm. Recently this technique became available on the Roche DISCOVERY ULTRA staining platform. With the DISCOVERY Proximity detection you can not only detect the presence/absence of a protein, but also to determine its functional states; i.e., whether it carries post-translational modifications or is present in complex with other proteins, in which cells it is expressed, and in which cell compartments the different states of the protein are present. By having the possibility on the DISCOVERY ULTRA system to add chromogenic IHC multiplexing you can create the advantage of visualizing which cells are undergoing protein interaction. In our recent publication we investigated the interaction between PD1/PDL1 where we studied tumour draining lymph nodes of melanomas and the primary tumours with proximity and chromogenic IHC multiplexing. Drugs targeting the PD1/PDL1 pathway have revolutionized the treatment of multiple cancer types including non-small cell lung cancer, renal cancer, and melanoma with a subset of patients experiencing durable responses. PD1/PDL1 blocking antibodies are believed to act primarily in the tumour microenvironment, by reinvigorating exhausted T cells and thereby reviving pre-existing anti-tumour immunity. In this presentation, we will review this technology by setting up PD1/PDL1 Proximity assay in combination with chromogenic IHC multiplexing with CD8, CD68 and CD11c.

Learning Objectives:

1. Obtain knowledge on how to set up the Proximity detection on Roche DISCOVERY ULTRA Platform

2. Obtain knowledge on how to add chromogenic IHC multiplexing to Proximity detection

3. Understand PD-1/PD-L1 interactions in Tumor Draining Lymph Nodes (TDLN) but not tumor correlate with prognosis in melanoma


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
MAY 19, 2022 8:00 AM PDT
MAY 19, 2022 8:00 AM PDT
Date: May 19, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Mass spectrometry (MS)-based proteomic technologies are increasingly applied in a clinical context for disease classific...
MAY 24, 2022 11:00 AM PDT
MAY 24, 2022 11:00 AM PDT
Date: May 24, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 7:00pm (CEST) NGS tumor profiling has become the mainstay of modern cancer therapy. Several NCCN-guided and FDA-approved therapies are c...
MAR 29, 2022 9:00 AM PDT
C.E. CREDITS
MAR 29, 2022 9:00 AM PDT
Date: March 29, 2022 Time: 09:00am (PDT), 12:00pm (EDT), 17:00 (GMT) Advances in molecular and immunodiagnostics are enabling a personalized, high-precision approach to health in many clin...
NOV 30, 2021 11:00 AM PST
C.E. CREDITS
NOV 30, 2021 11:00 AM PST
Date: November 30, 2021 Time: 11:00am (PDT), 2:00pm (EDT) In the recent years, measurable residual disease (MRD) assessment on multiple myeloma patients has gained increasing relevance. After...
Loading Comments...
Show Resources